Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
Go back to Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration| Regeneron (NASDAQ: REGN) | Delayed: 803.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $803.48 | 52 Week High | $592.36 | |||
| Open | $803.48 | 52 Week Low | $325.35 | |||
| Day High | $803.48 | P/E | 210.89 | |||
| Day Low | $803.48 | EPS | $3.81 | |||
| Volume | 158 | |||||
